Short Interest in Maze Therapeutics, Inc. (NASDAQ:MAZE) Rises By 50.9%

Maze Therapeutics, Inc. (NASDAQ:MAZE) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 2,460,000 shares, a growth of 50.9% from the September 15th total of 1,630,000 shares. Approximately 12.6% of the shares of the stock are sold short. Based on an average daily volume of 440,500 shares, the days-to-cover ratio is presently 5.6 days. Based on an average daily volume of 440,500 shares, the days-to-cover ratio is presently 5.6 days. Approximately 12.6% of the shares of the stock are sold short.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $29.12 on Thursday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $31.93. The stock’s fifty day moving average is $21.63 and its two-hundred day moving average is $15.24.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently bought and sold shares of MAZE. Bank of America Corp DE lifted its stake in Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after purchasing an additional 1,455 shares in the last quarter. CWM LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at approximately $28,000. New York State Common Retirement Fund purchased a new position in Maze Therapeutics during the first quarter worth approximately $25,000. Legal & General Group Plc boosted its stake in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Maze Therapeutics by 452.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after buying an additional 3,774 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MAZE. Guggenheim upped their target price on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. JPMorgan Chase & Co. increased their price objective on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a report on Monday, September 29th. Wedbush started coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and an average price target of $33.83.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.